Eczacibasi Ilac Pazarlama (EIP) has agreed to obtain the necessary regulatory approvals for the territory and to pay Vical upfront and milestone payments plus a specified transfer price in exchange for the rights to an exclusive license for the territory.
Previously, Allovectin-7, a plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and beta-2 microglobulin, has received orphan drug designation for the treatment of invasive and metastatic melanoma from the FDA’s Office of Orphan Products Development.
Vijay Samant, Vical’s president and CEO, said: “As we advance toward completion of enrollment in our Phase III trial of Allovectin-7 in patients with advanced metastatic melanoma, we are also looking ahead to commercialization opportunities in key global markets.
“As an established pharmaceutical company in Turkey with a significant cancer franchise, EIP has the expertise to guide Allovectin-7 through the Turkish approval process and the strength to launch and sell Allovectin-7 successfully in the Turkish market. We continue to explore licensing and distribution agreements in additional international markets.”